Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Re��onja Robert) .

61 - 70 / 205
Na začetekNa prejšnjo stran3456789101112Na naslednjo stranNa konec
61.
62.
63.
Rast in kakovost metasekvoje (Metasequoia glyptostroboides Hu et Cheng) v živem arhivu pri Ljubljani
Iza Petek, Gregor Božič, Dušan Jurc, Kristjan Jarni, Robert Brus, 2022, izvirni znanstveni članek

Povzetek: Analizirali smo živi arhiv metasekvoje (Metasequoia glyptostroboides Hu et Cheng) na obrečnem rastišču ob Savi pri Ljubljani. Osnovan je bil v letih 1993 in 1994 s sadikami, vzgojenimi iz originalnih semen z območja na Kitajskem, kjer je bila vrsta opisana (klasično nahajališče oz. locus classicus). Drevesa v nasadu so bila prvič izmerjena spomladi leta 2000 in nato še leta 2006, spomladi v letu 2020 pa smo meritve ponovili. V starosti 30 let je povprečno drevo merilo v višino 20,7 m, povprečni premer koreninskega vratu na višini debla 0,1 m je znašal 72,3 cm, povprečni premer debla na prsni višini pa 51,4 cm. Ugotovili smo, da je pogostnost reproduktivnih organov, torej storžev in moških cvetov, povezana s premerom in višino drevesa. Užlebljenost debla je zelo variabilna in povezana s premerom, zelo variabilno je tudi zmanjšanje premera z višino. Povezave med omenjenimi znaki in lego drevesa v nasadu nismo ugotovili. Svetloba oziroma lega v nasadu ni edini dejavnik, ki vpliva na lastnosti posameznega drevesa, vzrok je tudi genetska variabilnost med drevesi.
Ključne besede: Metasequoia glyptostroboides, semenski nasad, rast, kakovost, Slovenija
Objavljeno v DiRROS: 11.08.2022; Ogledov: 650; Prenosov: 175
.pdf Celotno besedilo (694,92 KB)

64.
Early-warning signals of individual tree mortality based on annual radial growth
Maxime Cailleret, Vasilis Dakos, Steven Jansen, Elisabeth M.R. Robert, Tuomas Aakala, Mariano M. Amoroso, Joe A. Antos, Christof Bigler, Harald Bugmann, Marco Caccianaga, Katarina Čufar, Tom Levanič, 2019, izvirni znanstveni članek

Povzetek: Tree mortality is a key driver of forest dynamics and its occurrence is projected to increase in the future due to climate change. Despite recent advances in our understanding of the physiological mechanisms leading to death, we still lack robust indicators of mortality risk that could be applied at the individual tree scale. Here, we build on a previous contribution exploring the differences in growth level between trees that died and survived a given mortality event to assess whether changes in temporal autocorrelation, variance, and synchrony in time-series of annual radial growth data can be used as early warning signals of mortality risk. Taking advantage of a unique global ring-width database of 3065 dead trees and 4389 living trees growing together at 198 sites (belonging to 36 gymnosperm and angiosperm species), we analyzed temporal changes in autocorrelation, variance, and synchrony before tree death (diachronic analysis), and also compared these metrics between trees that died and trees that survived a given mortality event (synchronic analysis). Changes in autocorrelation were a poor indicator of mortality risk. However, we found a gradual increase in interannual growth variability and a decrease in growth synchrony in the last %20 years before mortality of gymnosperms, irrespective of the cause of mortality. These changes could be associated with drought-induced alterations in carbon economy and allocation patterns. In angiosperms, we did not find any consistent changes in any metric. Such lack of any signal might be explained by the relatively high capacity of angiosperms to recover after a stress-induced growth decline. Our analysis provides a robust method for estimating early-warning signals of tree mortality based on annual growth data. In addition to the frequently reported decrease in growth rates, an increase in inter-annual growth variability and a decrease in growth synchrony may be powerful predictors of gymnosperm mortality risk, but not necessarily so for angiosperms.
Ključne besede: tree mortality, ring-width, forest, growth, resilience indicators, drought, biotic agents, variance
Objavljeno v DiRROS: 20.07.2022; Ogledov: 585; Prenosov: 386
.pdf Celotno besedilo (2,19 MB)
Gradivo ima več datotek! Več...

65.
Priporočila za zobozdravstveno obravnavo odraslih bolnikov z rakom glave in vratu v Sloveniji, zdravljenih z obsevanjem
Aleš Fidler, Aleksandar Aničin, Vojislav Didanovič, Tadej Dovšak, Boris Gašpirc, Aleš Grošelj, Andrej Kansky, Matic Koren, Jana Krapež, Hojka Kuralt, Marko Kuralt, Boštjan Lanišnik, Romana Mance Kristan, Jošt Pavčič, Luka Prodnik, Peter Pukl, Tadej Ostrc, Milan Kuhar, Eva Skalerič, Robert Šifrer, Valerija Skopec, Primož Strojan, 2022, izvirni znanstveni članek

Povzetek: Priporočila za zobozdravstveno obravnavo bolnikov z rakom glave in vratu (RGV) v Sloveniji, zdravljenih z obsevanjem sledijo priporočilom The Royal College of Surgeons of England v sodelovanju z The British Society for Disability and Oral Health, dopolnjujejo Priporočila za obravnavo bolnikov z rakom glave in vratu v Sloveniji in hkrati upoštevajo obstoječe zmožnosti slovenskega zdravstvenega sistema. Namen priporočil je prepre-čevanje oz. zmanjšanje zapletov v ustni votlini, ki nastanejo zaradi obsevanja. Opredeljujejo način zobozdravstvene oskrbe pred, med in po zdravljenju raka na vseh treh nivojih zobozdra-vstvene oskrbe, kar zagotavlja njeno pravočasnost in dostopnost. Priporočila predstavljajo poenoteno mnenje vseh deležnikov na področju zobozdravstvene obravnave bolnikov z RGV v državi.
Ključne besede: onkologija, zobozdravstvena obravnava, obsevanje, ustna votlina, priporočila
Objavljeno v DiRROS: 14.07.2022; Ogledov: 555; Prenosov: 188
.pdf Celotno besedilo (1,45 MB)

66.
In memoriam: izr. prof. dr. Sonja Horvat Marolt – v spomin (1930 – 2022)
Robert Brus, 2022, drugi sestavni deli

Objavljeno v DiRROS: 12.07.2022; Ogledov: 592; Prenosov: 176
.pdf Celotno besedilo (89,69 KB)

67.
Good survival of broadleaf tree species in a four-year-old plantation in the Slovenian Karst
Nina Škrk, Kristjan Jarni, Robert Brus, 2022, izvirni znanstveni članek

Povzetek: Six broadleaf tree species (Celtis australis L. – Mediterranean hackberry, Quercus petraea (Matt.) Liebl. – sessile oak, Fagus sylvatica L. – European beech, Prunus avium L. – wild cherry, Juglans regia L. – Persian walnut and Acer pseudoplatanus L. – sycamore maple) were planted in 2012 in a trial in the Slovenian Karst on two sites differing in productivity to test their suitability for use in the conversion of old pine stands into ecologically more stable broadleaf forests and to investigate their possible response to the harsher growth conditions predicted in the future. The selected economically interesting tree species have higher timber quality than broadleaves which regenerate naturally (e.g., Ostrya carpinifolia, Fraxinus ornus, Quercus cerris). Measurements were taken in 2017, after four growth seasons. All planted species except Fagus sylvatica had a high survival rate. In total, 70% of all seedlings survived, which shows promising potential. The survival rate was higher at the site on flat terrain than at the site on a slope. Prunus avium was the most successful of all planted species in terms of survival rate, at 83%, and other measured parameters (height, height increment, stem diameter, vitality and quality), and Fagus sylvatica was the least successful, with a survival rate of only 20%. Celtis australis had the highest survival rate, at 87%. Acer pseudoplatanus had the largest differences in measured parameters between the more and less productive sites among all planted species. Quercus petraea showed high resistance to xeric conditions and is expected to be the most successful in conversions. All planted species except Fagus sylvatica show favourable initial potential for the future conversion of Karst pine forests.
Ključne besede: forest conversion, broadleaves, survival rate, seedlings quality, climate change
Objavljeno v DiRROS: 28.06.2022; Ogledov: 2101; Prenosov: 959
.pdf Datoteka (3,13 MB)

68.
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Tanja Čufer, Katja Mohorčič, Maximilian J Hochmair, 2022, izvirni znanstveni članek

Povzetek: Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77years (range, 48–91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47–69), whereas it was 68% (95% CI, 50–82) in treatment-naïve and 50% (95% CI, 35–65) in pretreated patients. The median progression-free survival was 9.5months (95% CI, 4.7–14.3), whereas it was 10.6months (95% CI, 5.5–15.7) in first-line and 9.1months (95% CI, 3.1–15.1) in pretreated patients. After a median follow-up of 11.0months, the median overall survival was 18.2 months (95% CI, 13.2–23.1). In patients with measurable brain metastases (n=11), the intracranial ORR was 46% (95% CI, 17–77). Capmatinib showed a manageable safety profile. Grade⩾3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.
Ključne besede: non-small cell lung carcinoma -- drug therapy -- genetics, molecular targeted therapy, real-world data, capmatinib, targeted therapy
Objavljeno v DiRROS: 24.06.2022; Ogledov: 703; Prenosov: 541
.pdf Celotno besedilo (943,38 KB)
Gradivo ima več datotek! Več...

69.
70.
Iskanje izvedeno v 0.34 sek.
Na vrh